Adage Capital Partners
KPTI icon

Adage Capital Partners’s Karyopharm Therapeutics KPTI Stock Holding History

Adage Capital Partners’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.1M Buy
1,806,322
+1,385,000
+329% +$10.6M 0.02% 686
2025
Q4 		$3.1M Hold
421,322
– – ﹤0.01% 809
2025
Q3 		$2.76M Hold
421,322
– – ﹤0.01% 784
2025
Q2 		$1.82M Hold
421,322
– – ﹤0.01% 767
2025
Q1 		$1.58M Sell
421,322
-1
-0% -$9 ﹤0.01% 774
2024
Q4 		$4.27M Buy
421,323
+133,334
+46% +$1.61M 0.01% 730
2024
Q3 		$3.59M Hold
287,989
– – 0.01% 744
2024
Q2 		$3.75M Buy
287,989
+54,656
+23% +$905K 0.01% 738
2024
Q1 		$5.29M Buy
233,333
+122,446
+110% +$2.15M 0.01% 691
2023
Q4 		$1.44M Buy
+110,887
New +$1.49M ﹤0.01% 752
2023
Q1 		– Sell
-51,381
Closed -$2.62M – 956
2022
Q4 		$2.62M Buy
+51,381
New +$3.56M 0.01% 798
2021
Q2 		– Sell
-89,987
Closed -$14.2M – 1039
2021
Q1 		$14.2M Sell
89,987
-74,346
-45% -$15.7M 0.03% 571
2020
Q4 		$38.2M Sell
164,333
-49,862
-23% -$11.6M 0.08% 262
2020
Q3 		$46.9M Sell
214,195
-2,388
-1% -$584K 0.12% 185
2020
Q2 		$61.5M Sell
216,583
-31,652
-13% -$9.36M 0.16% 150
2020
Q1 		$71.5M Sell
248,235
-4,232
-2% -$1.17M 0.21% 116
2019
Q4 		$72.6M Buy
252,467
+139,134
+123% +$30.2M 0.18% 146
2019
Q3 		$16.4M Buy
+113,333
New +$15.4M 0.04% 412

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Adage Capital Partners's KPTI Position: Q1 2026 in Review

Adage Capital Partners increased its Karyopharm Therapeutics (KPTI) stake by 329% in Q1 2026, buying an estimated $10.6M and bringing the position to 1,806,322 shares worth $10.1M. The position accounts for 0.02% of the portfolio, ranked #686.

Adage Capital Partners first reported a position in KPTI in Q3 2019 and has held it in 18 quarters since. The position peaked at $72.6M in Q4 2019. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Adage Capital Partners held 1,806,322 shares of Karyopharm Therapeutics worth $10.1M as of Q1 2026.
  • Adage Capital Partners bought 1,385,000 Karyopharm Therapeutics shares in Q1 2026, an estimated $10.6M.
  • Karyopharm Therapeutics made up 0.02% of Adage Capital Partners's portfolio in Q1 2026, its #686 holding.
  • Adage Capital Partners first reported a position in Karyopharm Therapeutics in Q3 2019 and has held it in 18 quarters since.
  • Adage Capital Partners's Karyopharm Therapeutics position peaked at $72.6M in Q4 2019.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.